Trial Profile
Pasireotide for Prevention of Hypoglycemia in Patients With Hyperinsulinemic Hypoglycemia
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Pasireotide (Primary)
- Indications Hyperinsulinaemia; Hypoglycaemia
- Focus Therapeutic Use
- 14 Jun 2018 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 17 Feb 2017 New trial record